StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note released on Saturday morning. The firm issued a hold rating on the stock.
Separately, Ascendiant Capital Markets decreased their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research note on Monday, November 11th.
View Our Latest Research Report on NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Stock Performance
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Further Reading
- Five stocks we like better than NovaBay Pharmaceuticals
- What is the S&P/TSX Index?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How Can Investors Benefit From After-Hours Trading
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
